Evidence map›Paper›PMID 29317654›Full record

ArticleScientific reports2018

Response speed control of helicity inversion based on a "regulatory enzyme"-like strategy.

Shiho Sairenji, Shigehisa Akine, Tatsuya Nabeshima

Abstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Shiho SairenjiFaculty of Pure and Applied Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8571, Japan.
Shigehisa AkineGraduate School of Natural Science and Technology / Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, Kakuma-machi, Kanazawa, 920-1192, Japan. akine@se.kanazawa-u.ac.jp.ORCID http://orcid.org/0000-0003-0447-5057
Tatsuya NabeshimaFaculty of Pure and Applied Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8571, Japan. nabesima@chem.tsukuba.ac.jp.ORCID http://orcid.org/0000-0003-1269-7725

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In biological systems, there are many signal transduction cascades in which a chemical signal is transferred as a series of chemical events. Such successive reaction systems are advantageous because the efficiency of the functions can be finely controlled by regulatory enzymes at an earlier stage. However, most of artificial responsive molecules developed so far rely on single-step conversion, whose response speeds have been difficult to be controlled by external stimuli. In this context, developing artificial conversion systems that have a regulation step similar to the regulatory enzymes has been anticipated. Here we report a novel artificial two-step structural conversion system in which the response speed can be controlled based on a regulatory enzyme-like strategy. In this system, addition of fluoride ion caused desilylation of the siloxycarboxylate ion attached to a helical complex, resulting in the subsequent helicity inversion. The response speeds of the helicity inversion depended on the reactivity of the siloxycarboxylate ions; when a less-reactive siloxycarboxylate ion was used, the helicity inversion rate was governed by the desilylation rate. This is the first artificial responsive molecule in which the overall response speed can be controlled at the regulation step separated from the function step.

Indexed as

Models, BiologicalAllosteric RegulationCircular DichroismEnzyme ActivationEnzymesMolecular StructureStructure-Activity RelationshipEnzymes

Identifiers

PMID29317654
PMCPMC5760571

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.